HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease: A multicentre study

Judit Bajor, Zsolt Szakács, Márk Juhász, M. Papp, Dorottya Kocsis, Éva Szegedi, Ildikó Földi, Nelli Farkas, P. Hegyi, A. Vincze

Research output: Article

4 Citations (Scopus)

Abstract

Background and purpose: Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes. Methods: We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997 and included those patients, who (a) were diagnosed with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time of data collection. HLA typing was performed to determine DQB1*02 allele dose. Patients were divided into risk groups by DQB1*02 allele dose, as follows: high-, intermediate- and low-risk groups corresponded to a double, single and zero doses, respectively. We used ANOVA and Pearson's chi-squared test to explore association between HLA risk and clinical variables. Results: A total of 727 coeliac patients attended the clinics but only 105 (14.4%) patients were eligible for inclusion. High, intermediate and low HLA risk patients comprised 35.3%, 52.3% and 12.3% of the study population, respectively. Double dose of HLA-DQB1*02 was more frequent in patient with high tTGA level (>10 times the upper limit of normal; p = 0.045). Gene dose was not associated with younger age at diagnosis (p = 0.549), gender (p = 0.739), more severe diagnostic histology (p = 0.318), more frequent classical presentation (p = 0.846), anaemia (p = 0.611), metabolic bone disease (p = 0.374), dermatitis herpetiformis (p = 0.381) and autoimmune diseases (p = 0.837). Conclusions: Our study shows a significant gene dose effect in terms of tTGA level at diagnosis, but no significant association between HLA-DQB1*02 allele dose and the clinical outcomes in CD.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalInternational Journal of Immunogenetics
Volume46
Issue number2
DOIs
Publication statusPublished - ápr. 1 2019

Fingerprint

Celiac Disease
Multicenter Studies
Phenotype
Alleles
Histocompatibility Testing
Abdomen
Genes
Dermatitis Herpetiformis
Glutens
Metabolic Bone Diseases
Autoimmune Diseases
Anemia
Histology
Analysis of Variance
T-Lymphocytes
Population
HLA-DQB1 antigen

ASJC Scopus subject areas

  • Immunology
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease : A multicentre study. / Bajor, Judit; Szakács, Zsolt; Juhász, Márk; Papp, M.; Kocsis, Dorottya; Szegedi, Éva; Földi, Ildikó; Farkas, Nelli; Hegyi, P.; Vincze, A.

In: International Journal of Immunogenetics, Vol. 46, No. 2, 01.04.2019, p. 74-81.

Research output: Article

Bajor, Judit ; Szakács, Zsolt ; Juhász, Márk ; Papp, M. ; Kocsis, Dorottya ; Szegedi, Éva ; Földi, Ildikó ; Farkas, Nelli ; Hegyi, P. ; Vincze, A. / HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease : A multicentre study. In: International Journal of Immunogenetics. 2019 ; Vol. 46, No. 2. pp. 74-81.
@article{ecbe9840be434827aed2fb632c951670,
title = "HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease: A multicentre study",
abstract = "Background and purpose: Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes. Methods: We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997 and included those patients, who (a) were diagnosed with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time of data collection. HLA typing was performed to determine DQB1*02 allele dose. Patients were divided into risk groups by DQB1*02 allele dose, as follows: high-, intermediate- and low-risk groups corresponded to a double, single and zero doses, respectively. We used ANOVA and Pearson's chi-squared test to explore association between HLA risk and clinical variables. Results: A total of 727 coeliac patients attended the clinics but only 105 (14.4{\%}) patients were eligible for inclusion. High, intermediate and low HLA risk patients comprised 35.3{\%}, 52.3{\%} and 12.3{\%} of the study population, respectively. Double dose of HLA-DQB1*02 was more frequent in patient with high tTGA level (>10 times the upper limit of normal; p = 0.045). Gene dose was not associated with younger age at diagnosis (p = 0.549), gender (p = 0.739), more severe diagnostic histology (p = 0.318), more frequent classical presentation (p = 0.846), anaemia (p = 0.611), metabolic bone disease (p = 0.374), dermatitis herpetiformis (p = 0.381) and autoimmune diseases (p = 0.837). Conclusions: Our study shows a significant gene dose effect in terms of tTGA level at diagnosis, but no significant association between HLA-DQB1*02 allele dose and the clinical outcomes in CD.",
keywords = "coeliac disease, gene dose, HLA-DQ2, Homozygosis, Phenotype",
author = "Judit Bajor and Zsolt Szak{\'a}cs and M{\'a}rk Juh{\'a}sz and M. Papp and Dorottya Kocsis and {\'E}va Szegedi and Ildik{\'o} F{\"o}ldi and Nelli Farkas and P. Hegyi and A. Vincze",
year = "2019",
month = "4",
day = "1",
doi = "10.1111/iji.12415",
language = "English",
volume = "46",
pages = "74--81",
journal = "International Journal of Immunogenetics",
issn = "1744-3121",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease

T2 - A multicentre study

AU - Bajor, Judit

AU - Szakács, Zsolt

AU - Juhász, Márk

AU - Papp, M.

AU - Kocsis, Dorottya

AU - Szegedi, Éva

AU - Földi, Ildikó

AU - Farkas, Nelli

AU - Hegyi, P.

AU - Vincze, A.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background and purpose: Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes. Methods: We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997 and included those patients, who (a) were diagnosed with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time of data collection. HLA typing was performed to determine DQB1*02 allele dose. Patients were divided into risk groups by DQB1*02 allele dose, as follows: high-, intermediate- and low-risk groups corresponded to a double, single and zero doses, respectively. We used ANOVA and Pearson's chi-squared test to explore association between HLA risk and clinical variables. Results: A total of 727 coeliac patients attended the clinics but only 105 (14.4%) patients were eligible for inclusion. High, intermediate and low HLA risk patients comprised 35.3%, 52.3% and 12.3% of the study population, respectively. Double dose of HLA-DQB1*02 was more frequent in patient with high tTGA level (>10 times the upper limit of normal; p = 0.045). Gene dose was not associated with younger age at diagnosis (p = 0.549), gender (p = 0.739), more severe diagnostic histology (p = 0.318), more frequent classical presentation (p = 0.846), anaemia (p = 0.611), metabolic bone disease (p = 0.374), dermatitis herpetiformis (p = 0.381) and autoimmune diseases (p = 0.837). Conclusions: Our study shows a significant gene dose effect in terms of tTGA level at diagnosis, but no significant association between HLA-DQB1*02 allele dose and the clinical outcomes in CD.

AB - Background and purpose: Magnitude of gluten-specific T-cell responses in coeliac disease (CD) might be dependent on HLA-DQ2 gene dose. We aimed to investigate the effects of HLA-DQB1*02 allele dose on clinical outcomes. Methods: We reviewed the charts of all coeliac patients attending to three Hungarian university clinics after 1997 and included those patients, who (a) were diagnosed with CD, (b) underwent high-resolution HLA typing and (c) were ≥18 years at the time of data collection. HLA typing was performed to determine DQB1*02 allele dose. Patients were divided into risk groups by DQB1*02 allele dose, as follows: high-, intermediate- and low-risk groups corresponded to a double, single and zero doses, respectively. We used ANOVA and Pearson's chi-squared test to explore association between HLA risk and clinical variables. Results: A total of 727 coeliac patients attended the clinics but only 105 (14.4%) patients were eligible for inclusion. High, intermediate and low HLA risk patients comprised 35.3%, 52.3% and 12.3% of the study population, respectively. Double dose of HLA-DQB1*02 was more frequent in patient with high tTGA level (>10 times the upper limit of normal; p = 0.045). Gene dose was not associated with younger age at diagnosis (p = 0.549), gender (p = 0.739), more severe diagnostic histology (p = 0.318), more frequent classical presentation (p = 0.846), anaemia (p = 0.611), metabolic bone disease (p = 0.374), dermatitis herpetiformis (p = 0.381) and autoimmune diseases (p = 0.837). Conclusions: Our study shows a significant gene dose effect in terms of tTGA level at diagnosis, but no significant association between HLA-DQB1*02 allele dose and the clinical outcomes in CD.

KW - coeliac disease

KW - gene dose

KW - HLA-DQ2

KW - Homozygosis

KW - Phenotype

UR - http://www.scopus.com/inward/record.url?scp=85063073562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063073562&partnerID=8YFLogxK

U2 - 10.1111/iji.12415

DO - 10.1111/iji.12415

M3 - Article

C2 - 30779476

AN - SCOPUS:85063073562

VL - 46

SP - 74

EP - 81

JO - International Journal of Immunogenetics

JF - International Journal of Immunogenetics

SN - 1744-3121

IS - 2

ER -